Backlash against Johnson Johnson's COVID-19 vaccine is real and risky – here's how to make its rollout a success
- Written by Tinglong Dai, Associate Professor of Operations Management & Business Analytics, Johns Hopkins Carey Business School, Johns Hopkins University School of Nursing

More than 50 million Americans have received at least one dose of either the Pfizer or Moderna COVID-19 vaccine. So far, Americans have been largely brand-agnostic, but that’s about to change as a new vaccine rolls out.
The Johnson & Johnson vaccine has been hailed...